St. John's Wort And Kava In The Treatment Of Major Depressive Disorder With Comorbid Anxiety

Phase 2

Completed

• Conditions: Depressive Disorder, Major; Anxiety Disorders

• Registration Number: NCT00451516
• Lead Sponsor: The University of Queensland

Brief Summary

SJW has the greatest evidence of herbal medicine efficacy in treating MDD. In treating anxiety, kava has the greatest evidence of efficacy. As comorbidity of MDD and anxiety commonly occurs, it is conceivable that a combination of an established antidepressant agent such as SJW and an established anxiolytic agent such as kava may effectively treat MDD presenting with comorbid anxiety. It is possible that a beneficial synergistic effect may also occur between SJW and kava, improving the treatment outcomes in MDD with comorbid anxiety, than by the individual substances alone. Determination of this is not addressed in this study due to limitations of time and resources. The determination of the strength of the SJW-kava combination will be ascertained by comparing similar trials using SJW and kava mono-therapy in addressing MDD and GAD.

The hypothesis is that a combination of SJW and kava will reduce MDD occurring with comorbid anxiety more than placebo.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-03
• Study First Submitted: 2007-03-22
• Study First Submitted QC: 2007-03-22
• Study First Posted: 2007-03-23
• Primary Completion: 2007-10
• Study Completion: 2007-10
• Status Verified: 2008-05
• Last Update Submitted: 2008-05-16
• Last Update Posted: 2008-05-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
BAI
DASS
BDI II

Secondary Outcome Measures

Name	Time	Method
WHOQOL
Daily Mood Monitoring Form

Trial Locations

Locations (1)

RBWH; 🇦🇺 Brisbane, Queensland, Australia